CCIA
CLDX icon

Campbell & Co Investment Adviser’s Celldex Therapeutics CLDX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,530
Closed -$282K – 1174
2025
Q1 		$282K Buy
+15,530
New +$347K 0.02% 863
2024
Q2 		– Sell
-19,166
Closed -$804K – 1081
2024
Q1 		$804K Buy
+19,166
New +$787K 0.07% 489
2022
Q3 		– Sell
-8,052
Closed -$217K – 732
2022
Q2 		$217K Sell
8,052
-640
-7% -$18.6K 0.06% 579
2022
Q1 		$296K Buy
8,692
+1,092
+14% +$34.9K 0.08% 479
2021
Q4 		$294K Sell
7,600
-3,500
-32% -$153K 0.1% 368
2021
Q3 		$599K Buy
11,100
+3,100
+39% +$145K 0.2% 163
2021
Q2 		$268K Buy
+8,000
New +$220K 0.11% 354

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return